References
- Bloomfield C D, Shuma C, Regal L, Phillip P P, Hossfeld D K, Hagemeijer A M, et al. Long term survival of patients with acute myeloid leukemia. A third follow up of the Fourth International Workshop on chromosomes in leukemia. Cancer 1997; 80: 2191–2198
- Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Rees J, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. The Medical research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 100: 2322–2333
- Bloomfield C D, Lawrence D, Byrd J C, Carroll A, Pettanati M J, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173–4179
- Burnett A K, Wheatley K, Goldstone A H, Stevens R F, Hann I M, Rees J H, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400
- Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903
- Zittoun R A, Mandelli F, Willemze R, Witte T D, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223
- Burnett A K, Goldstone A H, Stevens R MF, Hann I M, Rees J KH, Gray R G, et al. Randomized comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700–708
- Bishop J, Lowenthal R, Joshua D, Mathews J P, Todd D, Cobcroft R, et al. Australian Leukaemia Study Group: etoposide in acute non-lymphocytic leukaemia. Blood 1990; 75: 27–32
- Bishop J F, Matthews J P, Young G AR, Szer J, Gillett A, Joshua D, et al. A randomized trial of high dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710–1717
- Sirohi B, Powles R, Singhal S, Smith K, Jones R L, Saso R, et al. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. Leuk Lymphoma 2008; 49: 2284–2290
- Bradstock K F, Matthews J P, Lowenthal R M, Baxter H, Catalano J, Brighton T, et al. A randomized trial of high- versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481–488
- Gilliland D G, Griffin J D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542
- Schlenk R F, Doehner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogentically normal acute myeloid leukaemia. N Engl J Med 2008; 358: 1909–1918
- Kern W, Haferlach C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukaemia. Cancer 2008; 112: 4–16